MannKind(NASDAQ) MNKD

Current Price$4.14

Market Cap$1.28B

Since IPO (2004)-94%

5 Year-5%

1 Year+1%

1 Month+8%

MannKind last closing stock price
Metric	Price	Date
Last close	USD 4.13	2026-07-24

MannKind stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+2.48%	USD 4.03	2026-07-17
1 month	+7.55%	USD 3.84	2026-06-24
3 month	+52.96%	USD 2.70	2026-04-24
Year to date	-27.16%	USD 5.67	2025-12-31
1 year	+1.23%	USD 4.08	2025-07-24
3 year	-7.4%	USD 4.46	2023-07-25
5 year	-5.49%	USD 4.37	2021-07-23
Since inception	-94.47%	USD 70.40	2004-07-28

MannKind Financials at a Glance

Market Cap

$1.28B

Revenue (TTM)

$360.78M

Net Income (TTM)

-$23.91M

EPS (TTM)

-$0.08

P/E Ratio

-52.95

Dividend

$0.00

Beta (Volatility)

1.11 (Average)

Dividend

$0.00

Beta (Volatility)

1.11 (Average)

Price

$4.14

Volume

9,444,208

Open

$4.06

Price

$4.14

Volume

9,444,208

Open

$4.06

Previous Close

$4.13

Daily Range

$3.98 - $4.23

52-Week Range

$2.23 - $6.51

Estimated Earnings Date

Aug 5, 2026

Dividend

$0.00

Beta (Volatility)

1.11 (Average)

Price

$4.14

Volume

9,444,208

Open

$4.06

Previous Close

$4.13

Daily Range

$3.98 - $4.23

52-Week Range

$2.23 - $6.51

Estimated Earnings Date

Aug 5, 2026

MNKD News

What This MannKind Filing Reveals About Three Years of Underperformance

Jonathan PoncianoJul 20, 2026

What This MannKind Director Sale Signals With $32.7 Million in Quarterly Royalties Revenue Potentially at Risk

Jonathan PoncianoJul 20, 2026

Page 1

MNKD: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About MannKind

MannKind makes medicines that patients breathe in instead of inject. These products help people manage diabetes and lung diseases easily. The company also builds wearable devices to deliver treatments.

Medicine You Can Breathe

Afrezza: Inhaled human insulin powder that helps adults with diabetes manage their blood sugar.
Tyvaso DPI: Breath-powered treatment for lung-related blood pressure issues, commercialized by a partner.
Furoscix: Wearable device and medicine combination used to treat fluid buildup in heart failure patients.
V-Go: Mechanical insulin delivery patch that provides steady and mealtime doses without multiple injections.

Making Big Moves

Acquired scPharma in October 2025 to expand into treatments for heart failure.
Expanded a drug development agreement with United Therapeutics in August 2025.
Purchased the V-Go product line from Zealand in May 2022.
Partnered with Cipla to launch inhaled insulin in India in December 2025.

Why Their Tech Matters

MannKind uses its Technosphere platform to turn liquid medicines into powders for deep lung delivery. It operates a dedicated manufacturing facility in Connecticut to produce these complex drug-device products.

The Latest Numbers

Revenue reached $112 million in Q4 2025, up 45.8% from Q4 2024.
Gross profit was $87.8 million in Q4 2025, up 53.6% year-over-year.
Operating income worsened to -$7.7 million in Q4 2025 from $26.5 million.
Net income fell to -$15.9 million in Q4 2025, worsening from $7.4 million in Q4 2024.

Bottom Line

MannKind has evolved from a single-product company into a diversified developer of inhaled therapies. Its focus on specialized drug delivery and strategic acquisitions supports its expansion in the biopharmaceutical market.

AI Generated • May 3, 2026

Industry

Biotechnology

Sector

Health Care

Employees

592

CEO

Michael E. Castagna, MBA

Website

www.mannkindcorp.com

Headquarters

Danbury, CA 91362, US

MNKD Financials

Key Financial Metrics (TTM)

Gross Margin

75.96%

Operating Margin

3.71%

Net Income Margin

-6.63%

Return on Equity

45.59%

Return on Capital

9.19%

Return on Assets

-3.21%

Earnings Yield

-1.89%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.28B

Shares Outstanding

308.95M

Volume

9.44M

Avg. Volume

5.83M

Financials (TTM)

Gross Profit

$274.05M

Operating Income

$13.40M

EBITDA

$27.55M

Operating Cash Flow

$18.83M

Capital Expenditure

-$6.12M

Free Cash Flow

$12.72M

Cash & ST Invst.

$133.86M

Total Debt

$436.67M

MannKind Performance Analysis

MannKind annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 99,770,000	32.2%
2023	2023-12-31	USD 198,962,000	99.4%
2024	2024-12-31	USD 285,504,000	43.5%
2025	2025-12-31	USD 348,966,000	22.2%

MannKind sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	-2.3%
Q3	2025-09-30	7.3%
Q4	2025-12-31	36.3%
Q1	2026-03-31	-19.5%

MannKind annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -0.34	4.7%
2023	2023-12-31	USD -0.04	-86.9%
2024	2024-12-31	USD 0.10	N/A
2025	2025-12-31	USD 0.02	-80.8%

MannKind sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	-94.9%
Q3	2025-09-30	1119.0%
Q4	2025-12-31	-291.4%
Q1	2026-03-31	-10.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$90.17M

+15.1%

Gross Profit

$68.33M

+12.3%

Gross Margin

75.78%

N/A

Market Cap

$1.28B

N/A

Market Cap/Employee

$2.16M

N/A

Employees

592

N/A

Net Income

-$16.62M

-226.3%

EBITDA

$2.45M

-90.9%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$133.86M

-26.3%

Total Debt

$436.67M

+824.2%

Accounts Receivable

$28.74M

-0.6%

Inventory

$49.17M

+70.2%

Long Term Debt

$423.79M

+3703.9%

Short Term Debt

$12.88M

-64.3%

Return on Assets

-3.21%

N/A

Return on Invested Capital

2.20%

N/A

Free Cash Flow

-$7.52M

-12.2%

Operating Cash Flow

-$5.64M

+11.5%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

BHVNBiohaven Ltd.

BHVNBiohaven Ltd.$14.32-2.25%

JANXJanux Therapeutics, Inc.

JANXJanux Therapeutics, Inc.$15.33-2.48%

ABCLAbCellera Biologics Inc.

ABCLAbCellera Biologics Inc.$5.31-6.35%

IMCRImmunocore Holdings plc

IMCRImmunocore Holdings plc$35.00-1.44%

AUPHAurinia Pharmaceuticals Inc.

AUPHAurinia Pharmaceuticals Inc.$15.35+0.72%

HRMYHarmony Biosciences Holdings, Inc.

HRMYHarmony Biosciences Holdings, Inc.$35.32-1.34%

SIONSionna Therapeutics, Inc.

SIONSionna Therapeutics, Inc.$45.70+3.72%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

INTCIntel

INTCIntel$92.32-0.08%

NOKNokia

NOKNokia$9.10-0.06%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$7.42-0.04%

SOFISoFi Technologies

SOFISoFi Technologies$16.46-0.01%

FFord Motor Company

FFord Motor Company$14.37+0.02%

AALAmerican Airlines Group

AALAmerican Airlines Group$14.48+0.07%

CLFCleveland-Cliffs

CLFCleveland-Cliffs$11.93+0.09%

Questions About MNKD

What is the current price of MannKind?

MannKind is trading at $4.13 per share.

What is the 52-week range for MannKind?

Over the past 52 weeks, MannKind has traded between $2.23 and $6.51.

How much debt does MannKind have?

As of the most recent reporting period, MannKind reported total debt of $436.67M.

How much cash does MannKind have on hand?

MannKind reported $52.83M in cash and cash equivalents in its most recent financial results.

What is MannKind’s dividend yield?

MannKind does not currently have a dividend yield.

MannKind(NASDAQ) MNKD

MannKind Financials at a Glance

MNKD News

What This MannKind Filing Reveals About Three Years of Underperformance

What This MannKind Director Sale Signals With $32.7 Million in Quarterly Royalties Revenue Potentially at Risk

What This MannKind Sale Signals With Tyvaso Royalties at $32.7 Million

Why This MannKind Insider Stock Sale Matters Less Than a 9% Royalty at Risk

Is MannKind a Stock to Sell After Its CEO Let Go of 363,200 Shares?

Why MannKind Stock Tumbled on Thursday

Is MannKind Stock a Buy or Sell After the CEO Sold Nearly 66,000 Shares?

MannKind (MNKD) Q2 Revenue Rises 6%

MNKD: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About MannKind

Medicine You Can Breathe

Making Big Moves

Why Their Tech Matters

The Latest Numbers

Bottom Line

MNKD Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

MannKind Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About MNKD

What is the current price of MannKind?

What is the 52-week range for MannKind?

How much debt does MannKind have?

How much cash does MannKind have on hand?

What is MannKind’s dividend yield?

Premium Investing Services